| Literature DB >> 35967526 |
Swapna Nuguri1, Meenakshi Swain2, Michelle De Padua2, Swarnalata Gowrishankar2.
Abstract
Introduction: Renal manifestations associated with hematolymphoid malignancies are known. Primary or secondary involvement of the kidney by lymphomatous infiltration has various clinical presentations. Acute kidney injury is not an uncommon finding in relation to lymphomatous interstitial infiltration proven on kidney biopsy. However, diagnosing it solely on renal biopsy remains a challenge and needs expertise and aid of immunohistochemistry as the prognosis is dismal.Entities:
Keywords: Acute kidney injury; lymphomatous infiltrate; renal lymphoma
Year: 2022 PMID: 35967526 PMCID: PMC9364996 DOI: 10.4103/ijn.ijn_345_21
Source DB: PubMed Journal: Indian J Nephrol ISSN: 0971-4065
Clinical details and follow-up
| Case number | Age in (years)/Sex | Clinical presentation | Serum. Creatinine (mg/dl) | IHC | Diagnosis NHL | Follow-up |
|---|---|---|---|---|---|---|
| 1 | 6/M | ARF as initial presentation, Hepatic SOL, Fever, Anemia | 1.9 | CD20+, CD3- | High-grade B-cell lymphoma | Patient died after 3 weeks of diagnosis |
| 2 | 47/M | History of NHL since three years, now ARF | 4 | CD20+, CD3- | Diffuse large B-cell lymphoma | LTFU |
| 3 | 50/M | History of Thymoma, post CT and RT, now abdominal pain | 5.6 | CD20-, CD3+ | High Grade T-cell lymphoma | LTFU |
| 4 | 45/M | ARF primary presentation, Abdominal lymph nodes, | 4.6 | CD20+, CD3- | Diffuse large B-cell lymphoma | Patient died within one month of diagnosis (CNS Bleed |
| 5 | 25/M | Unexplained ARF | 3.5 | CD20+, CD3- | Diffuse large B-cell lymphoma | LTFU |
| 6 | 46/F | History of NHL, 6 cycles of chemotherapy, now ARF | 3.2 | CD20+, CD3- | B-cell lymphoma | LTFU |
| 7 | 28/M | Rapidly progressing renal failure (2 weeks) | 4.4 | CD20+, CD3- | Diffuse large B-cell lymphoma | No systemic disease found; chemotherapy started |
| 8 | 4/M | Unexplained ARF, acute uric acid nephropathy, oliguria for 7 days | 4 | CD20+, CD3- | Diffuse large B-cell lymphoma | Patient died within 5 days (severe hyperuricemia) alive |
| 9 | 27/M | Small joints pain. ARF on hemodialysis | 9.6 mg% | CD 20+, CD3- | B-cell lymphoma | |
| 10 | 11/M | RPRF | 8.0 | CD 20-, CD3+ | T-Acute lymphoblastic lymphoma | Died due to sepsis |
| 11 | 35/M | Diagnosed case of NHL, ARF | 4.8 | CD3+, CD 20- | T-cell lymphoma | Alive, on dialysis |
| 12 | 50/M | Diagnosed case of CLL, RPRF, | 5.5 | CD 20+, CD3- | B-cell lymphoma | Alive, on dialysis |
Cases 3 and 7 are primary renal lymphoma and the others are renal involvement in systemic lymphoma, ARF: acute renal failure, SOL: space occupying lesion, NHL: Non-Hodgkins lymphoma, CT-RT chemo and radiotherapy, RPRF: rapidly progressing renal failure, CLL: chronic lymphocytic leukemia, symbol ‘- ‘is negative, symbol ‘+’: positive, LTFU: lost to follow-up
Figure 1Typing of lymphomatous interstitial infiltrate
Figure 2Kidney biopsy showing interstitial involvement by small to medium-sized atypical lymphoid cells. H and E, 1 is ×10, 2 and 3 is ×200, 4 is ×400
Figure 3IHC on kidney biopsy shows interstitial lymphomatous infiltrate is CD 20 positive in 1, CD3 positive in 2, TDT positive in 3, occasional CD20 positive in 4, CD3 positive in reactive lymphoid cells, and negative in atypical cells in 5. ×400
Type of lymphoma with renal involvement
| NHL | Our study ( | Shi-Jun Li[ | L Corlu | Tornroth | Javaugue | Shakeeb Ahmed Yunus |
|---|---|---|---|---|---|---|
| DLBCL | 41.6% (5) | 20% (4) | 17%(6) | 40% (2) | 15% (8) | 63% (12) |
| NHL B-cell | 16.6% (2) | 10%(MALT MCL each 1)(2) | 17% (6) | 20% (1) | 21% (10) | 21% (4) |
| ILBCL | 0 | 0 | 0 | 40% (2) | 1 | 0 |
| WM, myeloma | 0 | 0 | 35% (12) | 0 | 42% (21+1) | 0 |
| CLL | 8.3% (1) | 40% (8) | 29% (10) | 0 | 21% (11) | 0 |
| LPL | 0 | 10% (2) | 0 | 0 | 0 | 0 |
| High-grade T-cell lymphoma | 8.3% (1) | 20% (4) | 0 | 0 | 0 | 15.7% (3) |
| T ALL | 16.6% (2) | 0 | 0 | 0 | 0 | 0 |
DLBCL: diffuse large B-cell lymphoma, LPL lymphoplasmacytic lymphoma, WM-Waldenstrom macroglobulinemia, ILBCL- Intravascular large B-cell lymphoma, TALL- T-acute lymphoblastic lymphoma/leukemia, MALT: mucosa-associated lymphoid tissue lymphoma, MCL: mantle cell lymphoma